Godavari Drugs Fund Raise of ₹44.12 Cr

Godavari Drugs Q2 FY27 Results: Net Profit ₹1 Cr, Up 0.0% YoY

Godavari Drugs Ltd reported revenue from operations of ₹28.2 Cr (+6.0% YoY) and net profit of ₹1 Cr (+0.0% YoY) for Q2 FY27.

Key figure

Net profit ₹1 Cr · +0.0% YoY

Godavari Drugs Board Meeting Date

Godavari Drugs will hold a board meeting on 11 November 2026 to consider unaudited results for the quarter and half year ended 30 September 2026. The trading window stays closed until 48 hours after the results are declared.

Godavari Drugs Convertible Warrants

Godavari Drugs allotted 7,86,690 equity shares to promoter-category allottees on conversion of warrants. The balance consideration of Rs 5.25 Crore was received at an issue price of Rs 89.

Value

₹5.25 Cr

Godavari Drugs Other Announcement

Godavari Drugs filed its quarterly shareholding pattern for the period ended 30 September 2026. The filing is a routine Regulation 31 disclosure with no transaction.

Godavari Drugs Other Announcement

Godavari Drugs Limited changed its Corporate Identification Number (CIN) following an alteration to its Memorandum of Association's Object Clause. The Ministry of Corporate Affairs registered the change on October 16, 2026.

Godavari Drugs Debt & Borrowing: ₹34 Cr

Godavari Drugs Limited's board approved availing working capital limits of Rs. 34 Crore from ICICI Bank. The facility is within existing shareholder-approved borrowing limits.

Value

₹34.00 Cr

Om Metallogic Fund Raise

Om Metallogic Ltd intimated a board meeting on 14 November 2026 to approve rights issue issue price, entitlement ratio, record date and issue dates. The rights issue follows BSE in-principle approval.

Virinchi Fund Raise of ₹30 Cr

Virinchi's board approved a Rs 30 Crore preferential issue of 2 crore convertible warrants at Rs 15 each. Subject to EGM approval, allottees include promoter Viswanath Kompella.

Value

₹30.00 Cr

Execution

Warrant tenure not exceeding 18 months from allotment

IIFL Finance Fund Raise of ₹6,414 Cr

IIFL Finance's board approved a preferential issue of convertible preference shares and warrants worth Rs.6,414.20 Crore. Shareholder approval is needed at a 4 December EGM.

Value

₹6,414 Cr

Bajaj Finance Fund Raise of ₹5,800 Cr

Bajaj Finance's special committee approved issuing 5.74 crore warrants to promoter Bajaj Finserv at ₹1,010 each. The issue raises about ₹5,800 crore.

Value

₹5,800 Cr

Cholamandalam Investment & Finance Company Fund Raise of ₹5,000 Cr

Cholamandalam Investment sent shareholders a postal ballot notice seeking approval for a Rs 5,000 crore QIP. E-voting runs November 10 to December 9, 2026.

Value

₹5,000 Cr

Execution

Allotment to be completed within 365 days of shareholder approval

HB Leasing & Finance Co Fund Raise

HB Leasing's board discussed fund-raising options on November 9, 2026, including equity and preference shares. No quantum or pricing is decided; advisers will be consulted.